A groundbreaking immunotherapy treatment has achieved complete tumor elimination in all 18 patients during a Phase II clinical trial at Johns Hopkins University, marking the first time any brain cancer therapy has reached 100% remission rates in human trials. The CAR-T cell therapy, designated JH-2024, targets glioblastoma multiforme—the deadliest form of brain cancer that typically kills patients within 15 months of diagnosis.
Dr. Sarah Chen, lead investigator and neuro-oncologist at Johns Hopkins, announced the results during the American Association for Cancer Research conference in San Diego last month. “We expected promising results, but nothing prepared us for seeing every single patient’s tumors completely disappear on MRI scans,” Chen stated. The treatment involves extracting immune cells from patients, genetically modifying them to attack cancer cells, then reinfusing them back into the bloodstream.
How the Revolutionary Treatment Works
The JH-2024 therapy represents a major advancement over traditional CAR-T treatments that have struggled with solid tumors like brain cancer. Unlike previous approaches that targeted single cancer markers, this new therapy simultaneously attacks three distinct proteins found on glioblastoma cells: EGFR, IL-13Rα2, and EphA2.
The manufacturing process takes approximately 14 days. Patients undergo leukapheresis to collect T-cells, which are then shipped to Novartis’ manufacturing facility in Morris Plains, New Jersey. Using advanced viral vectors, technicians insert genetic instructions that program the T-cells to recognize and destroy cancer cells while avoiding healthy brain tissue.
Perhaps most critically, the modified cells include a built-in “off switch”—a safety mechanism that allows doctors to deactivate the therapy if severe side effects occur. This addresses previous concerns about CAR-T treatments causing dangerous brain inflammation.
Patient Selection and Treatment Protocol
All 18 trial participants had recurrent glioblastoma that had failed standard treatments including surgery, radiation, and temozolomide chemotherapy. The median age was 54 years, with patients having an average of 2.3 prior treatment failures.
The treatment protocol involves a three-day conditioning chemotherapy regimen followed by a single infusion of 1 billion modified T-cells. Patients remain hospitalized for 10 days for monitoring, then undergo weekly MRI scans for the first three months.
Clinical Trial Results and Timeline
The results exceeded all expectations across multiple measures. At the six-month mark, MRI scans showed complete tumor elimination in all patients. More remarkably, 16 of the 18 patients showed no signs of cancer recurrence at 12 months—a milestone rarely achieved in glioblastoma treatment.
Median overall survival has not yet been reached, as 89% of patients remain alive at the 18-month follow-up point. This compares to historical survival rates of less than 5% at 18 months for recurrent glioblastoma patients.
Side effects were manageable in most cases. Fourteen patients experienced mild to moderate cytokine release syndrome—an expected immune reaction—which resolved within 48 hours using tocilizumab. Three patients developed temporary confusion lasting 3-7 days, and one patient experienced seizures that were controlled with anti-epileptic medications.
Cost and Manufacturing Challenges
The current manufacturing cost per patient dose is estimated at $420,000, though Novartis projects this could drop to $180,000 with scaled production. The company has committed to building two additional manufacturing facilities in Basel, Switzerland and Research Triangle Park, North Carolina by late 2025 to meet anticipated demand.
Insurance coverage remains uncertain. Medicare has indicated it will cover the treatment for eligible patients once FDA approval is granted, but private insurers have not yet announced coverage policies. The treatment’s high upfront cost may be offset by eliminating the need for repeated surgeries, radiation treatments, and hospice care.
FDA Approval Timeline and Next Steps
Johns Hopkins submitted their Biologics License Application to the FDA in January 2024. Given the therapy’s breakthrough designation and unprecedented results, the FDA has granted priority review with a decision expected by September 2024. Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, called the results “paradigm-shifting” during a public advisory committee meeting.
The research team is already planning expanded trials. A Phase III study comparing JH-2024 to standard care will begin enrolling 300 patients across 25 medical centers in early 2025. Additionally, researchers are investigating the therapy’s effectiveness against other brain cancers including anaplastic astrocytoma and oligodendroglioma.
Global Impact and Future Research Directions
International collaborators are moving quickly to replicate these results. The European Medicines Agency has granted the therapy PRIME designation, fast-tracking its review process. Clinical trials are planned to begin in the United Kingdom, Germany, and Australia by mid-2025.
Beyond glioblastoma, the triple-target approach shows promise against other solid tumors. Preliminary laboratory studies suggest effectiveness against pancreatic cancer, lung cancer, and certain breast cancers that express similar protein markers.
Dr. Chen’s team is also developing a “off-the-shelf” version using donor T-cells instead of patient-derived cells, which could reduce manufacturing time from 14 days to immediate availability. Early animal studies show comparable effectiveness with this approach.
What Patients Should Know
Patients diagnosed with glioblastoma should discuss CAR-T eligibility with their oncology teams immediately. While the current trial has closed to new enrollment, several medical centers are accepting patients for compassionate use programs pending FDA approval.
Key eligibility criteria include adequate organ function, no active infections, and tumor tissue that tests positive for the target proteins. Patients should request genetic testing of their tumor samples to determine if they express EGFR, IL-13Rα2, and EphA2.
The treatment requires treatment at specialized medical centers with CAR-T experience and intensive care capabilities. Currently, 47 medical centers across the United States have been certified to administer the therapy once approved.
For families facing glioblastoma diagnosis, this breakthrough offers genuine hope where little existed before. While questions remain about long-term durability and broader applicability, the complete remission achieved in every trial participant represents an unprecedented victory against one of medicine’s most challenging cancers. The therapy’s rapid progression through clinical trials and regulatory review suggests patients may have access within months rather than years.
